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Special NBs (with opsomyoclonus or OMC; IV-S) have an excellent prognosis (85% 2 year survival) vs. conventional NBs (29% 2 y.s.) in our patient pool; this was inexplicable by standard prognostic factors alone. We studied tumor biopsies prior to therapy from 46 special (12 Stage 11-OMC, 34 IV-S) and 48 conventional (12 Stage 11, 36 Stage I11 or IV) Thrombocytopenia was found in five (12.5%)of 40 children with evidence of HIV infection. Age of the patients at time of diagnosis of thrombocytopenia ranged from two months to two years; platelet counts were less than 50,00O/cmm in all and less than 10,00O/cmm in three. Two of five patients had thrombocytopenia at the time of diagnosis of HIV infection while three others developed it during the course of their illness. Three of five patients manifested bleeding (petechiae, echymosis, and epistaxis). Bone marrow examination revealed increased numbers of megakaryocytes in all. Increased levels of platelet associated antibody (PAIgC) were found in 212 patients testee. Four patients received intravenous gamma globulin (IVGG) in a dose of 2-3 g/kg over a 3-5 day period. Only one patient had a significant increase in platelet count (from 32,000 to 350,000 /cmm) two days after a five day course of IVGG therapy, but the count returned to 40,00O/cmm in two weeks. Two patients whose platelet count did not improve after IVGG received prednisone and in one there was a moderate but transient increase in the platelet count. We conclude that immune thrombocytopenia occurs in children with HIV infection and that the rate of response to IVGG appears to be lower than that reported in HIV associated ITP in adults or non-HIV associated ITP in children.
DECREASED TUMOR CYTOLYSIS OF NEUTKOPHILS (PMN) FROM PATIENTS WITH CHRONIC GRANULOMATOUS DISEASE (CGD).
Robert L. Roberts, Bonnie J. Ank, and E. Richard l 790 Stiehm. UCLA School of Medicine, Los Angeles, CA.
Human PMN are capable of lysing tumor cells after activation by stimuli such as phorbol myristate acetate (PMA). We compared PMN from normals and CGD patients for their ability to mediate turnor lysis and inhibit lysis by normal mononuclear cells (MNC). The CGD patients (whose PMN lack the ability to generate reactive oxygen intermediates, ROI) include 2 males (X-linked) and 3 females (autosomal). Human PMN were isolated on discontinuous Percoll gradients, and cytotoxicity was measured by 5 1~r release from the K562 cell line. PMN were activated by exposure to PMA (100ng/ml) at 4 ' C .
In an 18 hr assay, normal PMN lysed 33.1*3.9% (n=17) of the target cells and CGD PMN lysed 10.8 * 2.5% (12 experiments). Decreasing the effector:target ratio to 25:l did not alter the lytic ability of normal PMN (31.1*4.5%,n=3) but did decrease the lysis by CGD PMN (6.4 * 1.7%. p<.025). Lysis by both normal and CGD PMN could be almost totally blocked by cytochalasin B (5ug/ml), indicating a role for the cytoskeleton. Preliminary studies indicate that lysis by CGU PMN (but not normal PMN) is enhanced by both tumor necrosis factor and interferon-gamma. The addition of normal PMN to normal MNC decreased natural killer (NK) lysis from 68.8 Thus, tumor cytolysis by PMN appears to be dependent on both oxidative and non-oxidative mechanisms, whereas inhibition Of NK cytotoxicity requires the generation of ROI. Intracranial extension of rhabdomyosarcoma (RMS) has been identified as a major cause of failure in parameningeal sites. Fifteen of 214 (7%) patients with nonparameningeal RMS had intracranial extension threatened or proven at diagnosis. The primary sites included: orbit (a), neck (21, cheek (2), parotid ( I ) , oropharynx (I), and temporalis (1). Computerized tomographic scans in 13 cases were helpful in detecting the intracranial extension and defining the anatomical extent of the primary. One or more patterns of CNS extension were seen in the 15 patients: parameningeal extension (8), bony erosion of the orbit ( 7 ) , infraorbital fissure involvement (4), brain metastases ( 3 ) , meningeal metastases (2), cavernous sinus extension (2) and invasion of the optic nerve (1). Five of 6 cases receiving intrathecal chemotherapy and cranial radiotherapy according to guidelines for parameningeal sites survived. Metastases to the meninges and brain carried the gravest prognosis with no survivors. In the remaining patients 10/11 are alive at a median of 11 months from diagnosis. Careful evaluation of all patients with head and neck RMS may reveal threatened or proven intracranial extension. In these cases management according to guidelines for parameningeal head and neck sites is recommended. Inmunostaining with these antibodies was used to rapidly visualize elevated amunts of dihydrofolate reductase in m-resistant ostcosarmm cells. Further delineation of the exact mechanisns(s) accountin9 for the MIX resistance in these human osteosarcrma cells is currently under investigation.
